JP2016521258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521258A5 JP2016521258A5 JP2016503422A JP2016503422A JP2016521258A5 JP 2016521258 A5 JP2016521258 A5 JP 2016521258A5 JP 2016503422 A JP2016503422 A JP 2016503422A JP 2016503422 A JP2016503422 A JP 2016503422A JP 2016521258 A5 JP2016521258 A5 JP 2016521258A5
- Authority
- JP
- Japan
- Prior art keywords
- hemoglobin
- lysine
- pao
- conjugate
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000001554 Hemoglobins Human genes 0.000 claims 45
- 108010054147 Hemoglobins Proteins 0.000 claims 45
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000002202 Polyethylene glycol Substances 0.000 claims 15
- 229920001223 polyethylene glycol Polymers 0.000 claims 15
- 210000000056 organ Anatomy 0.000 claims 13
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 10
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 8
- 208000028867 ischemia Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000007475 hemolytic anemia Diseases 0.000 claims 6
- 208000014674 injury Diseases 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 208000032467 Aplastic anaemia Diseases 0.000 claims 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 208000025911 acute intestinal ischemia Diseases 0.000 claims 4
- 201000006781 acute vascular insufficiency of intestine Diseases 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 206010007625 cardiogenic shock Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 208000031225 myocardial ischemia Diseases 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- -1 succinimidyl Chemical group 0.000 claims 4
- 230000008733 trauma Effects 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 3
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 3
- 238000009098 adjuvant therapy Methods 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000002399 angioplasty Methods 0.000 claims 3
- 230000035939 shock Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010002091 Anaesthesia Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical group [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010021074 Hypoplastic anaemia Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010022971 Iron Deficiencies Diseases 0.000 claims 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims 2
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 241000097929 Porphyria Species 0.000 claims 2
- 208000010642 Porphyrias Diseases 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 201000010789 Spermatic Cord Torsion Diseases 0.000 claims 2
- 206010043356 Testicular torsion Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 231100000836 acute liver failure Toxicity 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 230000037005 anaesthesia Effects 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 208000005980 beta thalassemia Diseases 0.000 claims 2
- 208000022806 beta-thalassemia major Diseases 0.000 claims 2
- 239000003633 blood substitute Substances 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 2
- 239000001569 carbon dioxide Substances 0.000 claims 2
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 2
- 229940045200 cardioprotective agent Drugs 0.000 claims 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 238000002316 cosmetic surgery Methods 0.000 claims 2
- 230000002338 cryopreservative effect Effects 0.000 claims 2
- 208000029039 cyanide poisoning Diseases 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 238000013467 fragmentation Methods 0.000 claims 2
- 238000006062 fragmentation reaction Methods 0.000 claims 2
- 238000001631 haemodialysis Methods 0.000 claims 2
- 230000000322 hemodialysis Effects 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- 201000004108 hypersplenism Diseases 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 230000004199 lung function Effects 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000006353 oxyethylene group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000024241 parasitism Effects 0.000 claims 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 2
- 244000144977 poultry Species 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000000472 traumatic effect Effects 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 239000003357 wound healing promoting agent Substances 0.000 claims 2
- 125000003860 C1-C20 alkoxy group Chemical group 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 claims 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 claims 1
- 206010041660 Splenomegaly Diseases 0.000 claims 1
- 210000002376 aorta thoracic Anatomy 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- RHDWKUYFKXIIOF-OWOJBTEDSA-N bis[(3,6-dibromo-6-hydroxycyclohexa-2,4-dien-1-yl)methyl] (e)-but-2-enedioate Chemical compound OC1(Br)C=CC(Br)=CC1COC(=O)\C=C\C(=O)OCC1C(Br)(O)C=CC(Br)=C1 RHDWKUYFKXIIOF-OWOJBTEDSA-N 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000002016 colloidosmotic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 201000007647 intestinal volvulus Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801016P | 2013-03-15 | 2013-03-15 | |
| US61/801,016 | 2013-03-15 | ||
| PCT/US2014/030569 WO2014145755A1 (en) | 2013-03-15 | 2014-03-17 | Polyalkylene oxide valerate hemoglobin conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521258A JP2016521258A (ja) | 2016-07-21 |
| JP2016521258A5 true JP2016521258A5 (enExample) | 2017-04-20 |
| JP6657070B2 JP6657070B2 (ja) | 2020-03-04 |
Family
ID=51538084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503422A Active JP6657070B2 (ja) | 2013-03-15 | 2014-03-17 | ポリアルキレンオキシド吉草酸ヘモグロビン接合体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10821158B2 (enExample) |
| EP (1) | EP2968597B1 (enExample) |
| JP (1) | JP6657070B2 (enExample) |
| KR (1) | KR102238718B1 (enExample) |
| CN (1) | CN105188761B (enExample) |
| AU (1) | AU2014232540B2 (enExample) |
| BR (1) | BR112015023233A8 (enExample) |
| CA (1) | CA2906878C (enExample) |
| MX (1) | MX373193B (enExample) |
| WO (1) | WO2014145755A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10506829B2 (en) | 2016-02-26 | 2019-12-17 | Freelander Innovations USA, LLC | System and method for a vaporizer |
| CA3070172A1 (en) | 2017-07-18 | 2019-01-24 | VirTech Bio, Inc. | Blood substitutes comprising hemoglobin and methods of making |
| GB201721503D0 (en) * | 2017-12-20 | 2018-01-31 | Univ Essex | Modified globin proteins |
| WO2021037109A1 (en) * | 2019-08-29 | 2021-03-04 | Billion King International Ltd. | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof |
| US11535655B2 (en) * | 2019-12-06 | 2022-12-27 | Cheer Global Limited | Method of treating inflammatory bowel disease |
| WO2022184005A1 (en) | 2021-03-01 | 2022-09-09 | Billion King International Limited | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529719A (en) | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
| EP0206448B1 (en) * | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| CA1312009C (en) | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
| GB8710598D0 (en) | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
| US5234903A (en) | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
| US5650388A (en) | 1989-11-22 | 1997-07-22 | Enzon, Inc. | Fractionated polyalkylene oxide-conjugated hemoglobin solutions |
| US5250665A (en) | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
| ATE302019T1 (de) * | 1997-02-28 | 2005-09-15 | Univ California | Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen |
| KR100316154B1 (ko) | 1999-03-26 | 2001-12-12 | 노광 | 폴리에틸렌글리콜－헤모글로빈 결합체 |
| DE10031744A1 (de) | 2000-06-29 | 2002-01-17 | Sanguibio Tech Ag | Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung |
| DE10031740A1 (de) | 2000-06-29 | 2002-02-14 | Sanguibio Tech Ag | Künstliche Sauerstoffträger aus vernetztem modifizierten Human- oder Schweinehämoglobin mit verbesserten Eigenschaften, Verfahren zu ihrer technisch einfachen Herstellung aus gereinigtem Material in hohen Ausbeuten, sowie deren Verwendung |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| DE10220992A1 (de) | 2002-05-11 | 2003-12-04 | Sanguibiotech Ag | Verwendung eines oder mehrerer Sauerstoffträger, ausgewählt aus Hämoglobin, Myoglobin und Derivaten hiervon zur Behandlung einer Organfunktionsstörung infolge eines akuten Versorgungsmangels und zur Behandlung/Vermeidung einer Gewebeschädigung infolge einer solchen Störung |
| MXPA05000796A (es) | 2002-07-24 | 2005-04-19 | Hoffmann La Roche | Aditivos de acidos polialquilenglicolicos. |
| US20040072729A1 (en) | 2002-10-10 | 2004-04-15 | Sunbio Inc. | High oxygen affinity PEG-hemoglobin as treatment for brain stroke |
| CA2511494A1 (en) | 2002-12-23 | 2004-07-15 | Seetharama A. Acharya | Non-hypertensive polyethylene glycol-modified hemoglobin as oxygen carrier |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| DE10352692A1 (de) | 2003-11-12 | 2005-06-23 | Sanguibiotech Gmbh | Verwendung hypo-onkotischer Lösungen in das Blut addierbarer, hyperpolymerer Hämoglobine zur Behandlung eines Lungenödems |
| WO2006096774A2 (en) | 2005-03-07 | 2006-09-14 | Sangart, Inc. | Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers |
| NO2440239T3 (enExample) * | 2009-06-09 | 2018-02-10 | ||
| JP2015514718A (ja) | 2012-04-03 | 2015-05-21 | サンガート， インコーポレイテッド | スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法 |
-
2014
- 2014-03-17 JP JP2016503422A patent/JP6657070B2/ja active Active
- 2014-03-17 BR BR112015023233A patent/BR112015023233A8/pt not_active Application Discontinuation
- 2014-03-17 CN CN201480015028.0A patent/CN105188761B/zh active Active
- 2014-03-17 MX MX2015013263A patent/MX373193B/es active IP Right Grant
- 2014-03-17 AU AU2014232540A patent/AU2014232540B2/en active Active
- 2014-03-17 CA CA2906878A patent/CA2906878C/en active Active
- 2014-03-17 WO PCT/US2014/030569 patent/WO2014145755A1/en not_active Ceased
- 2014-03-17 EP EP14765388.5A patent/EP2968597B1/en active Active
- 2014-03-17 US US14/777,261 patent/US10821158B2/en active Active
- 2014-03-17 KR KR1020157027637A patent/KR102238718B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521258A5 (enExample) | ||
| JP2015514718A5 (enExample) | ||
| CN104411807B (zh) | 琥珀酰亚胺活化型硝酰化合物及其用于蛋白质硝酰化的使用方法 | |
| CN104395391A (zh) | 双重衍生化的壳聚糖纳米粒子以及制造和使用其用于体内基因转移的方法 | |
| JP2015514086A5 (enExample) | ||
| JP6668515B2 (ja) | ジアスピリン架橋ｐｅｇヘモグロビン | |
| US20070166278A1 (en) | Novel g-csf conjugates | |
| WO2012067138A1 (ja) | 新規なシチジン系代謝拮抗剤の高分子誘導体 | |
| JP6657070B2 (ja) | ポリアルキレンオキシド吉草酸ヘモグロビン接合体 | |
| JP2011507913A5 (enExample) | ||
| JP6358797B2 (ja) | 癌を処置するためのウミロリムスおよびその誘導体の使用 | |
| JP5281358B2 (ja) | 高分子、経上皮吸収促進剤、及び医薬用製剤 | |
| US20230123697A1 (en) | Therapeutic patch for gastrointestinal tract and method of manufacturing same | |
| JP7773169B2 (ja) | ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液 | |
| JPS63208523A (ja) | 酸素運搬剤 | |
| RU2025117117A (ru) | Фармацевтическая композиция для предупреждения или лечения заболевания "трансплантат против хозяина", содержащая производное GLP-2 или его конъюгат длительного действия | |
| CN118846100A (zh) | 一种肿瘤微环境响应型聚合物-药物偶联物及其制备方法和应用 | |
| CN104136038A (zh) | 体腔积液抑制剂 | |
| KR20030062467A (ko) | 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제 | |
| HK1219053B (zh) | 聚环氧烷戊酸酯血红蛋白缀合物 | |
| HK1207659B (zh) | 琥珀酰亚胺活化型硝酰化合物及其用於蛋白质硝酰化的使用方法 | |
| EP2694096A1 (en) | Melanocyte-stimulation hormone for suppressing inflammation reactions in hemodialysis |